Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma

被引：0
|
作者：
David T Yang
Ken H Young
Brad S Kahl
Stephanie Markovina
Shigeki Miyamoto
机构：
[1] University of Wisconsin School of Medicine and Public Health,Department of Pharmacology
[2] University of Wisconsin School of Medicine and Public Health,Department of Pathology and Laboratory Medicine
[3] University of Wisconsin School of Medicine and Public Health,Department of Medicine
[4] University of Wisconsin,Paul P. Carbone Comprehensive Cancer Center
[5] University of Wisconsin School of Medicine and Public Health,Program in Cellular and Molecular Biology and Medical Scientist Training Program
来源：
Molecular Cancer | / 7卷
关键词：
Bortezomib; Electrophoretic Mobility Shift Assay; Mantle Cell Lymphoma; Combination Index; Perillyl Alcohol;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
相关论文
共 50 条
  • [1] Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma
    Yang, David T.
    Young, Ken H.
    Kahl, Brad S.
    Markovina, Stephanie
    Miyamoto, Shigeki
    MOLECULAR CANCER, 2008, 7 (1)
  • [2] Bortezomib resistant constitutive NF-κB activation in mantle cell lymphoma
    Yang, David T.
    Young, Ken H.
    Kahl, Brad S.
    Miyamoto, Shigeki
    BLOOD, 2007, 110 (11) : 1015A - 1015A
  • [3] Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma
    A Moros
    V Rodríguez
    I Saborit-Villarroya
    A Montraveta
    P Balsas
    P Sandy
    A Martínez
    A Wiestner
    E Normant
    E Campo
    P Pérez-Galán
    D Colomer
    G Roué
    Leukemia, 2014, 28 : 2049 - 2059
  • [4] Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma
    Moros, A.
    Rodriguez, V.
    Saborit-Villarroya, I.
    Montraveta, A.
    Balsas, P.
    Sandy, P.
    Martinez, A.
    Wiestner, A.
    Normant, E.
    Campo, E.
    Perez-Galan, P.
    Colomer, D.
    Roue, G.
    LEUKEMIA, 2014, 28 (10) : 2049 - 2059
  • [5] Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma
    Jung, Hyun Joo
    Chen, Zheng
    Fayad, Luis
    Wang, Michael
    Romaguera, Jorge
    Kwak, Larry W.
    McCarty, Nami
    EXPERIMENTAL HEMATOLOGY, 2012, 40 (02) : 107 - 118
  • [6] Complexity of constitutive NF-kappaB activity as a therapeutic target in breast cancer cells
    Moiseeva, E.
    Heukers, R.
    Manson, M.
    EJC SUPPLEMENTS, 2006, 4 (12): : 180 - 180
  • [7] Constitutive Activation of p62/Sequestosome-1-Mediated Proteaphagy Regulates Proteolysis and Impairs Cell Death in Bortezomib-Resistant Mantle Cell Lymphoma
    Quinet, Gregoire
    Xolalpa, Wendy
    Reyes-Garau, Diana
    Profitos-Peleja, Nuria
    Azkargorta, Mikel
    Ceccato, Laurie
    Gonzalez-Santamarta, Maria
    Marsal, Maria
    Andilla, Jordi
    Aillet, Fabienne
    Bosch, Francesc
    Elortza, Felix
    Loza-Alvarez, Pablo
    Sola, Brigitte
    Coux, Olivier
    Matthiesen, Rune
    Roue, Gael
    Rodriguez, Manuel S.
    CANCERS, 2022, 14 (04)
  • [8] Role of monitoring NF-kappaB activity
    Senftleben, U
    SHOCK, 2004, 21 : 103 - 103
  • [9] The proteasome inhibitor bortezomib (PS-341) reverses constitutive activation of NF-kappaB pathway and promotes apoptosis in human cutaneous T cell lymphoma (CTCL)
    Sors, A
    Jean-Louis, F
    Dubertret, L
    Bachelez, H
    Michel, L
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 123 (02)
  • [10] Synergistic anti-tumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma
    Moros, Alexandra
    Rodriguez, Vanina
    Saborit-Villarroya, Ifigenia
    Montraveta, Arnau
    Balsas, Patricia
    Sandy, Peter
    Martinez, Antonio
    Normant, Emmanuel
    Perez-Galan, Patricia
    Campo, Elias
    Colomer, Dolors
    Roue, Gael
    CANCER RESEARCH, 2014, 74 (19)
12345